A once-weekly basal insulin is in development to help treat Type 2 diabetes. Researchers suggest that reducing the frequency of basal insulin injections might help treatment acceptance and adherence among people with the condition.
The insulin icodec, by Novo Nordisk, shows comparable efficacy and safety to once-daily insulin glargine U100 after a 26-week randomised phase 2 trial involving 247 participants who had not previously received long-term insulin treatment and whose Type 2 diabetes was inadequately controlled.
The results have been published in the New England Journal of Medicine.
